首页> 美国卫生研究院文献>Oncotarget >BRD4 facilitates DNA damage response and represses CBX5/Heterochromatin protein 1 (HP1)
【2h】

BRD4 facilitates DNA damage response and represses CBX5/Heterochromatin protein 1 (HP1)

机译:BRD4促进DNA损伤反应并抑制CBX5 /异染色质蛋白1(HP1)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Ovarian cancer (OC) is a heterogeneous disease characterized by defective DNA repair. Very few targets are universally expressed in the high grade serous (HGS) subtype. We previously identified that CHK1 was overexpressed in most of HGSOC. Here, we sought to understand the DNA damage response (DDR) to CHK1 inhibition and increase the anti-tumor activity of this pathway. We found BRD4 suppression either by siRNA or BRD4 inhibitor JQ1 enhanced the cytotoxicity of CHK1 inhibition. Interestingly, BRD4 was amplified and/or upregulated in a subset of HGSOC with statistical correlation to overall survival. BRD4 inhibition increased CBX5 (HP1α) level. CHK1 inhibitor induced DDR marker, γ-H2AX, but BRD4 suppression did not. Furthermore, nuclear localization of CBX5 and γ-H2AX was mutually exclusive in BRD4-and CHK1-inhibited cells, suggesting BRD4 facilitates DDR by repressing CBX5. Our results provide a strong rationale for clinical investigation of CHK1 and BRD4 co-inhibition, especially for HGSOC patients with BRD4 overexpression.
机译:卵巢癌(OC)是一种异质性疾病,其特征在于DNA修复缺陷。高度浆液性(HGS)亚型中普遍表达的靶标很少。我们先前发现CHK1在大多数HGSOC中均过表达。在这里,我们试图了解对CHK1抑制的DNA损伤反应(DDR)并增加该途径的抗肿瘤活性。我们发现siRNA或BRD4抑制剂JQ1抑制BRD4增强了CHK1抑制的细胞毒性。有趣的是,BRD4在HGSOC的一个子集中被扩增和/或上调,与总体存活率具有统计相关性。 BRD4抑制增加CBX5(HP1α)水平。 CHK1抑制剂可诱导DDR标记物γ-H2AX,但BRD4抑制则不会。此外,CBX5和γ-H2AX的核定位在BRD4和CHK1抑制的细胞中是互斥的,这表明BRD4通过抑制CBX5促进了DDR。我们的结果为CHK1和BRD4共同抑制的临床研究提供了有力的依据,尤其是对于BSOC4过表达的HGSOC患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号